Therapeutic Approaches to Type I Interferonopathies
- 20 April 2018
- journal article
- research article
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 20 (6) , 32
Abstract
To review recent scientific advances and therapeutic approaches in the expanding field of type I interferonopathies.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (Clinical Research Unit 249; LE 1074/4-2 to M.L.-K and TU 421/1-2 to V.T.)
This publication has 70 references indexed in Scilit:
- Type I interferon-mediated autoinflammation due to DNase II deficiencyNature Communications, 2017
- The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammationNature Immunology, 2017
- The Type I InterferonopathiesAnnual Review of Medicine, 2017
- Discriminating self from non-self in nucleic acid sensingNature Reviews Immunology, 2016
- Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1American Journal of Medical Genetics Part A, 2015
- Regulation of type I interferon responsesNature Reviews Immunology, 2013
- Type I interferonopathies: a novel set of inborn errors of immunityAnnals of the New York Academy of Sciences, 2011
- Aicardi-Goutières Syndrome and Systemic Lupus Erythematosus (SLE) in a 12-Year-Old Boy With SAMHD1 MutationsJournal of Child Neurology, 2011
- Expanding the phenotypic spectrum of lupus erythematosus in Aicardi‐Goutières syndromeArthritis & Rheumatism, 2010
- A Progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosisAnnals of Neurology, 1984